Format

Send to

Choose Destination
Immunol Rev. 2014 Jan;257(1):14-38. doi: 10.1111/imr.12136.

Adoptive immunotherapy for cancer.

Author information

1
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Abstract

Recent clinical success has underscored the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and durable clinical responses. This success has led to the broader evaluation of engineered T-lymphocyte-based adoptive cell therapy to treat a broad range of malignancies. In this review, we summarize concepts, successes, and challenges for the broader development of this promising field, focusing principally on lessons gleaned from immunological principles and clinical thought. We present ACT in the context of integrating T-cell and tumor biology and the broader systemic immune response.

KEYWORDS:

adoptive cell therapy; cancer; chimeric antigen receptor; immune modulation; immunotherapy; tumor microenvironment

PMID:
24329787
DOI:
10.1111/imr.12136
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center